BOSTON SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a
Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could
Alexion Pharmaceuticals Inc. completed the acquisition of Portola Pharmaceuticals Inc. in a deal worth about $1.41 billion.
Portola Pharmaceuticals, Inc. (Portola), a biopharmaceutical company that develops and commercializes treatments for thrombosis and other
Portola Pharmaceuticals Inc (PTLA) Q4 2024 Earnings Call Transcript. Here's Why Portola Pharmaceuticals Fell as Much as 45.4% Today. 3 Small-Cap Healthcare Stocks With Large-Cap Potential.
Alexion Pharmaceuticals, Inc. tender offer for Portola Pharmaceuticals, Inc. Public Merger Agreements $1.41 billion (including
Alexion Pharmaceuticals, Inc. today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. Alexion completed the acquisition through a tender offer and subsequent
About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel
Portola Pharmaceuticals, Inc, et al, Case No. 3:20-cv- VC. District Portola Pharmaceuticals, Inc. Securities Litigation c/o Epiq Class
Comments
5star story.